Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-01-26 1:36 pm Purchase |
2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 11,730 9.990% |
1,961 (+20.07%) |
Filing History |
| 2023-01-26 1:30 pm Unchanged |
2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
0 (Unchanged) |
Filing History |
| 2023-01-26 1:28 pm Sale |
2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 3,043,173 6.380% |
-2,947,666 (-49.20%) |
Filing History |
| 2022-12-05 4:30 pm Purchase |
2022-11-23 | 13G | OptiNose, Inc. OPTN |
ACORN BIOVENTURES, L.P. | 757,931 9.900% |
757,931 (New Position) |
Filing History |
| 2021-02-12 4:58 pm Purchase |
2020-12-18 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
ACORN BIOVENTURES, L.P. | 9,769 9.990% |
9,769 (New Position) |
Filing History |
| 2020-07-02 2:59 pm Purchase |
2020-06-15 | 13D | Cardiff Oncology, Inc. CRDF |
ACORN BIOVENTURES, L.P. | 5,990,839 9.990% |
4,303,279 (+255.00%) |
Filing History |